Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Molecular Biology

Background:

• Ischemic cardiomyopathy presents a significant global health challenge with limited therapeutic options.
• Endogenous revascularization strategies are being explored to improve myocardial function.
• Previous work demonstrated granulocyte-macrophage colony-stimulating factor (GMCSF) induces endothelial progenitor cell (EPC) production and stromal cell-derived factor-1alpha (SDF) acts as an EPC chemokine.

Purpose of the Study:

• To investigate the regional biological mechanisms underlying GMCSF and SDF therapy for ischemic cardiomyopathy.
• To assess the impact of GMCSF/SDF therapy on EPCs, neovascularization, and myocardial function.

Main Methods:

• Lewis rats with induced ischemic cardiomyopathy underwent GMCSF and SDF injections or saline control.
• Circulating EPC density was measured by flow cytometry.
• Vessel stability, perfusion, ATP levels, apoptosis, and myofilament density were assessed using immunofluorescence, confocal microangiography, and TUNEL assays.

Main Results:

• GMCSF/SDF therapy significantly increased circulating leukocyte and EPC concentrations.
• Enhanced stable vasculature and improved perfusion in the borderzone were observed.
• The therapy led to increased myocardial ATP levels, reduced cardiomyocyte apoptosis, and enhanced myofilament density.

Conclusions:

• GMCSF and SDF therapy effectively upregulates circulating EPCs and enhances vascular stability.
• This approach augments myocardial function by improving perfusion and reversing cellular ischemia.
• The therapy increases cardiomyocyte viability, offering a promising strategy for ischemic cardiomyopathy.